Vanda Pharmaceuticals Inc [VNDA] stock prices are up 5.73% to $4.98 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VNDA shares have gain 3.53% over the last week, with a monthly amount glided 3.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vanda Pharmaceuticals Inc [NASDAQ: VNDA] stock has seen the most recent analyst activity on October 31, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $18. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on July 11, 2024, and set its price target to $11. On February 25, 2022, downgrade downgraded it’s rating to Hold and revised its price target to $12 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $22 on May 12, 2021. Citigroup downgraded its rating to a Neutral but $14 remained the price target by the analyst firm on January 14, 2021. Citigroup upgraded its rating to Buy for this stock on October 29, 2020, but kept the price target unchanged to $14. In a note dated June 09, 2020, Citigroup downgraded an Neutral rating on this stock but restated the target price of $14.
The stock price of Vanda Pharmaceuticals Inc [VNDA] has been fluctuating between $3.71 and $6.75 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Vanda Pharmaceuticals Inc [NASDAQ: VNDA] shares were valued at $4.98 at the most recent close of the market. An investor can expect a potential return of 120.88% based on the average VNDA price forecast.
Analyzing the VNDA fundamentals
The Vanda Pharmaceuticals Inc [NASDAQ:VNDA] reported sales of 198.77M for trailing twelve months, representing a surge of 17.48%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.03 and Total Capital is -0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.75 points at the first support level, and at 4.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.10, and for the 2nd resistance point, it is at 5.23.
Ratios To Look Out For
It’s worth pointing out that Vanda Pharmaceuticals Inc [NASDAQ:VNDA]’s Current Ratio is 4.39. Further, the Quick Ratio stands at 4.37, while the Cash Ratio is 1.02. Considering the valuation of this stock, the price to sales ratio is 1.46, the price to book ratio is 0.54.
Transactions by insiders
Recent insider trading involved Polymeropoulos Mihael Hristos, President and CEO, that happened on Mar 06 ’25 when 10000.0 shares were purchased. President and CEO, Polymeropoulos Mihael Hristos completed a deal on Mar 05 ’25 to buy 10000.0 shares. Meanwhile, President and CEO Polymeropoulos Mihael Hristos bought 10000.0 shares on Mar 03 ’25.
